The U.S. Government Just Made Its Biggest Bet on Healthy Aging: Inside ARPA-H’s $144 Million PROSPR Program

Seven research teams. Three repurposed FDA-approved drugs. A retrotransposon-silencing HIV medication. And $144 million in federal funding. The ARPA-H PROSPR program is the most ambitious government commitment to extending healthy human lifespan ever assembled.

Presented By Our Partners

For most of medical history, aging was treated as a backdrop to disease rather than a disease itself. Physicians managed the consequences: cardiovascular decline, cognitive loss, frailty, metabolic dysfunction. The underlying process that made all of those outcomes more likely was considered largely off-limits, both scientifically and philosophically.

That consensus is now breaking down at an accelerating pace. In February 2026, the Advanced Research Projects Agency for Health (ARPA-H) announced $144 million in funding across seven research teams as part of a program called PROSPR: PROactive Solutions for Prolonging Resilience. The funding represents the largest single federal commitment to extending healthspan in American history, and its scope reaches well beyond any previous government-backed aging initiative.

PROSPR is not a bet on any single molecule or mechanism. It is a coordinated, multi-institution effort to build the tools, trial designs, and clinical evidence needed to establish healthspan medicine as a legitimate medical category. The program funds everything from a landmark multi-drug aging trial enrolling 726 healthy older adults, to a first-in-humans study of a repurposed HIV drug targeting so-called junk DNA, to a Stanford-led initiative to create a validated biological healthspan score. Taken together, the seven funded projects represent a quiet but historic turning point in how the United States approaches human aging.

What PROSPR Is and Why It Was Created

ARPA-H was established in 2022 to fund high-risk, high-reward medical research that falls outside the scope of traditional NIH grant structures. Modeled after DARPA, the agency is designed to pursue transformational breakthroughs rather than incremental advances. Its mission is to accelerate the development of biomedical technologies and therapies that would not otherwise attract conventional research funding.

PROSPR reflects that mandate. The program was built around a recognition that the tools to measure healthspan and the clinical trial designs to prove that aging-related decline can be modified simply do not yet exist at scale. Traditional clinical trials take decades because their endpoints are disease events: a heart attack, an Alzheimer’s diagnosis, a cancer. PROSPR aims to compress that timeline to three years or less by developing new biomarker-based healthspan scores that can detect aging-related decline early, before clinical disease appears.

The program’s organizing concept is “intrinsic capacity,” a framework developed by the World Health Organization to describe the composite of all physical and mental capabilities a person can draw on across their lifetime. Intrinsic capacity declines with age, but that decline is not linear or inevitable. PROSPR bets that it can be measured, slowed, and possibly reversed.

The VITAL-H Trial: Testing Three Drugs in 726 Healthy Older Adults

The centerpiece of the PROSPR portfolio is a clinical trial called VITAL-H, led by the Barshop Institute for Longevity and Aging Studies at UT Health San Antonio. The Barshop Institute received up to $38 million from ARPA-H to conduct the trial, the largest PROSPR award of any single institution.

VITAL-H stands for Validation and Intervention Testing for Aging, Longevity and Healthspan. The trial will enroll 726 adults in their 60s and assign them randomly to one of four groups: three active drug arms and one placebo arm. Participants will be followed for three years. The three drugs under investigation are rapamycin, dapagliflozin, and semaglutide. Each carries a distinct mechanism of action and a separate body of preclinical and early human evidence suggesting it may slow biological aging.

What makes VITAL-H unlike any previous aging trial is its participant profile. These are not people with diabetes, heart failure, or cancer. They are generally healthy adults entering their seventh decade of life, a population that the pharmaceutical industry has largely ignored because there is no approved indication for anti-aging treatment. VITAL-H is designed to generate exactly the kind of evidence that would be required to change that.

Rapamycin: The mTOR Inhibitor With Decades of Animal Data

Rapamycin is the most studied anti-aging compound in the VITAL-H protocol. The drug, originally developed as an immunosuppressant for organ transplant patients, works by inhibiting mTORC1, a protein complex that functions as a central regulator of cellular growth, metabolism, and autophagy. When mTOR signaling is chronically elevated, cells prioritize growth over maintenance; inhibiting it shifts resources toward cellular repair, waste clearance, and stress resistance.

The preclinical evidence for rapamycin’s geroprotective effects is the most robust of any compound in this class. Studies in model organisms have shown that decreased mTOR signaling extends mean lifespan by approximately 19 percent in the roundworm C. elegans, 24 percent in fruit flies, and up to 60 percent in laboratory mice. The ITP (Interventions Testing Program), a rigorous multi-site aging research consortium funded by the National Institute on Aging, has replicated life extension with rapamycin in mice across multiple cohorts and both sexes.

Human evidence has lagged behind animal data, partly because large, well-designed trials have not existed. The PEARL trial, published in 2025, found that low-dose intermittent rapamycin was well tolerated over 12 months in healthy adults and produced modest but meaningful improvements in cardiac diastolic function and microvascular endothelial signaling. Cardiac MRI assessments revealed statistically significant improvements in heart muscle relaxation, and nitric oxide-mediated vasodilation responses improved measurably. These are not surrogate endpoints for mortality, but they point toward the kinds of functional changes that distinguish healthy aging from accelerating decline.

VITAL-H will not resolve the rapamycin question definitively. Three years is too short to observe lifespan effects. But it will generate the largest and most rigorous human safety and biomarker dataset for low-dose rapamycin ever assembled, and it will do so in a population for whom no current standard of care exists.

Semaglutide: GLP-1’s Expanding Biology

The inclusion of semaglutide in VITAL-H reflects a broadening scientific understanding of what GLP-1 receptor agonists actually do in the body. Semaglutide, sold under the brand names Ozempic, Wegovy, and Rybelsus depending on formulation and indication, was developed for type 2 diabetes and later approved for obesity. Its mechanisms extend well beyond blood sugar management.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

GLP-1 receptors are expressed throughout the body, including in the brain, heart, kidneys, liver, and immune cells. Activation of these receptors has been associated with reduced systemic inflammation, improved mitochondrial function, slowed neurodegeneration, and favorable changes in body composition. The SELECT trial, published in 2023, demonstrated that semaglutide reduced major cardiovascular events by 20 percent in obese or overweight adults with established cardiovascular disease, even in the absence of diabetes. Subsequent analyses have suggested the cardiovascular benefit extends beyond weight loss alone.

In the VITAL-H context, semaglutide is being evaluated not as a weight-loss drug but as a potential modifier of the biological processes that drive aging at the cellular level. Whether GLP-1 signaling can meaningfully slow intrinsic capacity decline in generally healthy older adults has never been tested in a rigorous randomized trial. VITAL-H will provide the first controlled answer.

Dapagliflozin: The SGLT2 Inhibitor Entering the Aging Arena

Dapagliflozin (brand name Farxiga) belongs to the SGLT2 inhibitor class of drugs, which lower blood glucose by blocking reabsorption of glucose in the kidneys, prompting its excretion in urine. Like semaglutide, dapagliflozin was developed for type 2 diabetes and subsequently demonstrated benefits far beyond glycemic control. Clinical trials have shown meaningful reductions in cardiovascular mortality and hospitalization for heart failure, as well as slowed progression of chronic kidney disease, in patients with and without diabetes.

The mechanistic case for dapagliflozin as a geroprotective agent rests on its effects on energy sensing, cellular stress responses, and mitochondrial efficiency. SGLT2 inhibitors activate AMPK, a cellular energy sensor that promotes autophagy and mitochondrial biogenesis under nutrient-limited conditions. This overlaps substantially with the mechanisms implicated in caloric restriction-mediated longevity. Preclinical data from multiple model systems show that SGLT2 inhibition extends lifespan and healthspan, prompting serious interest from longevity researchers who view it as among the most pharmacologically accessible interventions available today.

Including dapagliflozin in VITAL-H alongside rapamycin and semaglutide creates a scientifically coherent trifecta: three drugs targeting distinct but mechanistically overlapping pathways that collectively influence the biology of cellular aging.

Brown University: Silencing the Junk DNA That May Be Driving Inflammation

While the Barshop Institute focuses on repurposing existing drugs, a team at Brown University is tackling a mechanism most physicians have never heard of. Professors Vera Gorbunova and John Sedivy received up to $22 million from ARPA-H to investigate retrotransposons as a primary driver of age-related inflammation, and to test whether silencing them with a repurposed HIV drug can slow biological aging.

Retrotransposons are ancient genetic sequences, sometimes described as “junk DNA,” that account for roughly 45 percent of the human genome. They are remnants of viral insertions that occurred over millions of years of evolution. In young, healthy cells, these sequences are kept dormant by epigenetic silencing mechanisms. With age, those silencing mechanisms weaken. Retrotransposons become increasingly active, producing RNA transcripts and even DNA copies that the immune system detects as foreign viral material.

The result is a form of chronic, low-grade immune activation that Gorbunova and Sedivy have linked to interferon signaling, a powerful antiviral defense pathway. When retrotransposons trigger interferon responses in aging tissues, the result is sterile inflammation: the immune system fights a phantom infection, damaging healthy tissue in the process. This mechanism has been implicated in neurodegeneration, cancer progression, metabolic dysfunction, and autoimmune conditions. In short, retrotransposon activation may be one of the central molecular triggers of what geroscientists call inflammaging, the persistent low-level inflammation that characterizes biological aging.

The Brown-led ARPA-H project will test Censavudine (also known as TPN-101), a drug originally developed to treat HIV, as a retrotransposon suppressor. Censavudine inhibits reverse transcriptase, the enzyme that retrotransposons use to copy themselves into DNA. By blocking this enzyme, the drug may prevent the junk DNA amplification cycle that fuels age-related immune activation. The clinical phase will enroll at least 200 healthy adults between ages 60 and 65 at three sites: the University of Rochester, UConn Health, and the University of Texas Medical Branch. Participants will receive Censavudine or placebo for 48 weeks.

This is arguably the most conceptually novel component of PROSPR. It frames aging as, in part, a viral-mimicry problem, one where the body’s own ancient genetic passengers become agents of deterioration. If Censavudine shows measurable effects on inflammatory biomarkers or biological age clocks, it will open an entirely new category of longevity therapeutics.

Stanford and the Healthspan Score: Measuring What Medicine Has Never Measured

A fifth dimension of PROSPR that has received less press attention but may carry the longest-term significance is Stanford University’s project to develop a validated, scalable healthspan score. The PROSPR-IC score (Intrinsic Capacity score) will draw on existing health datasets from multiple institutions and be validated against outcomes in a one-year lifestyle intervention using in-home digital health assessment technology.

The significance of this project is that without a validated healthspan measurement, the entire field of longevity medicine lacks a shared outcome metric. Mortality is easy to measure but takes decades. Disease onset is clinically meaningful but occurs too late in the trajectory to test prevention effectively. The PROSPR-IC score aims to fill that gap with a composite biomarker-derived measure of biological aging that can detect meaningful change within one to three years.

If validated, this score would do for longevity medicine what the A1c blood test did for diabetes: create a standardized, widely deployable tool that clinicians can use to identify people at risk, track treatment response, and make the case for preventive intervention before disease occurs.

Cambrian Bio and the mTORC1 Inhibitor Pipeline

Cambrian BioPharma, a longevity-focused drug development company, received up to $30.8 million from ARPA-H to advance its proprietary mTORC1 inhibitor candidates. One compound is slated to enter Phase 1 trials as part of the PROSPR program. Cambrian’s approach is not simply to use rapamycin but to develop next-generation molecules that inhibit the same pathway with greater selectivity and a more favorable side effect profile.

This component of PROSPR illustrates the program’s ambition to go beyond repurposing toward original drug development. If the VITAL-H trial demonstrates that mTOR inhibition has measurable healthspan effects in humans, Cambrian’s pipeline would be positioned to deliver a purpose-built version optimized for long-term use in healthy adults, exactly the population for whom standard rapamycin was never designed.

A New Era of Preventive Medicine

What unifies the PROSPR portfolio is a conceptual commitment that the broader medical establishment has been slow to embrace: that biological aging is a modifiable process, not an immutable one, and that intervening in generally healthy people before disease manifests is not only scientifically plausible but morally urgent.

The cost argument is compelling. Age-related chronic disease accounts for the majority of healthcare spending in the United States. The Centers for Disease Control estimates that 90 percent of the $4.5 trillion the U.S. spends on health care annually goes toward treating chronic and mental health conditions, the vast majority of which are diseases of aging. A therapy that extends the period of functional independence by even two or three years would generate savings that dwarf the cost of the research investment many times over.

ARPA-H’s decision to invest $144 million in PROSPR reflects a recognition, increasingly shared by researchers at the National Institute on Aging, the Hevolution Foundation, and the Longevity Science Panel, that the field has matured to a point where the question is no longer whether aging biology can be targeted but how best to design the trials that prove it.

The VITAL-H trial at UT San Antonio, the Censavudine trial led by Gorbunova and Sedivy, the Cambrian Bio mTOR inhibitor program, and Stanford’s healthspan scoring initiative represent four very different approaches to the same scientific frontier. They share a common framework: measure biological aging rigorously, intervene early, and build the evidence base that will allow clinicians to treat aging decline the way they treat cholesterol or blood pressure today.

What This Means for You

The PROSPR program will not produce clinical recommendations tomorrow. The VITAL-H trial is just beginning enrollment. The Censavudine trial has not yet entered its human phase. The Stanford healthspan score is still being validated. The timeline from trial initiation to clinical practice guidelines is typically measured in years, not months.

But the signal matters regardless of the timeline. The federal government has formally declared that aging is a legitimate target of medical intervention, and it has backed that declaration with the largest funding commitment the field has ever seen. That shift has practical consequences for how pharmaceutical companies, insurance systems, and medical schools will begin to orient their priorities over the next decade.

For those committed to longevity today, the actionable insight is this: the interventions most likely to emerge from programs like PROSPR will work best in people who have maintained their baseline biology. Rapamycin, semaglutide, and dapagliflozin all show their greatest effects in metabolically healthy individuals. Retrotransposon suppression is most effective when epigenetic silencing mechanisms are still partially intact. The foundations of your biology, how well you move, how consistently you sleep, how close to whole food your diet remains, and how effectively you manage stress, determine the substrate on which every future medical intervention will act.

The longevity drugs are coming. The federal infrastructure to validate them is now being built. The question for each person reading this is not whether the medicine will exist, but whether your biology will be positioned to benefit from it when it arrives.

The research institutions driving PROSPR are betting it will matter. The five pillars of foundational health, nutrition, sleep, movement, breathwork, and mindset, are how you make sure they are right about you specifically.

Sources: ARPA-H PROSPR Announcement; UT Health San Antonio Barshop Institute; Brown University ARPA-H Award; Science Magazine; Rapamycin for Longevity, PMC 2025; LINE-1 retrotransposons and interferon signaling, PubMed; Longevity.Technology

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.